Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE-RA: Ivarmacitinib in Moderate-to-Severe Active Rheumatoid Arthritis
ChiCTR2500106834Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ivarmacitinib in rheumatoid arthritis (RA), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: ACR20 response and HAQ-DI score. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2500106834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106834.